These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 37670350

  • 21. Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease.
    Deng M, Zhou H, Liang Z, Li Z, Wang Y, Guo W, Zhao AY, Li F, Mu Y, Zhao AZ.
    Biomolecules; 2022 Dec 27; 13(1):. PubMed ID: 36671438
    [Abstract] [Full Text] [Related]

  • 22. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K, Pushkov A, Zhanin I, Mazanova N, Trufanov S, Pakhomov A, Alexeeva A, Sladkov D, Asanov A, Fisenko A.
    Orphanet J Rare Dis; 2022 May 16; 17(1):199. PubMed ID: 35578305
    [Abstract] [Full Text] [Related]

  • 23. Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
    Tsukimura T, Shiga T, Saito K, Ogawa Y, Sakuraba H, Togawa T.
    Mol Genet Metab Rep; 2021 Sep 16; 28():100773. PubMed ID: 34136356
    [Abstract] [Full Text] [Related]

  • 24. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
    Perrone A, Mohamed S, Donadio V, Liguori R, Contin M.
    Molecules; 2021 Dec 03; 26(23):. PubMed ID: 34885938
    [Abstract] [Full Text] [Related]

  • 25. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H, Aoki M, Tsukimura T, Togawa T, Sakuraba H.
    PLoS One; 2015 Dec 03; 10(12):e0144958. PubMed ID: 26661087
    [Abstract] [Full Text] [Related]

  • 26. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T, Tsukimura T, Kawashima I, Sato A, Sakuraba H, Togawa T.
    Mol Genet Metab; 2017 Dec 03; 120(1-2):116-120. PubMed ID: 27756537
    [Abstract] [Full Text] [Related]

  • 27. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
    Yamashita S, Saotome M, Satoh H, Kajihara J, Mochizuki Y, Mizuno K, Nobuhara M, Miyajima K, Kumazawa A, Tominaga H, Takase H, Tawarahara K, Wakahara N, Matsunaga M, Wakabayashi Y, Matsumoto Y, Terada H, Sano M, Ohtani H, Urushida T, Hayashi H, Ishii S, Maruyama H, Maekawa Y.
    Circ J; 2019 Aug 23; 83(9):1901-1907. PubMed ID: 31308318
    [Abstract] [Full Text] [Related]

  • 28. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
    Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG.
    J Med Genet; 2022 Mar 23; 59(3):287-293. PubMed ID: 33495303
    [Abstract] [Full Text] [Related]

  • 29. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R, Rodrigues D, Assunção M, Macedo MF, Azevedo O, Cunha D, Oliveira P, Sá Miranda MC.
    Gene; 2014 Feb 15; 536(1):97-104. PubMed ID: 24334116
    [Abstract] [Full Text] [Related]

  • 30. Precision medicine in Fabry disease.
    Lenders M, Brand E.
    Nephrol Dial Transplant; 2021 Jun 22; 36(Suppl 2):14-23. PubMed ID: 34153986
    [Abstract] [Full Text] [Related]

  • 31. Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease.
    Alharbi FJ, Baig S, Auray-Blais C, Boutin M, Ward DG, Wheeldon N, Steed R, Dawson C, Hughes D, Geberhiwot T.
    J Inherit Metab Dis; 2018 Mar 22; 41(2):239-247. PubMed ID: 29294190
    [Abstract] [Full Text] [Related]

  • 32. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
    Shiga T, Tsukimura T, Kubota T, Togawa T, Sakuraba H.
    Intern Med; 2024 Jun 01; 63(11):1531-1537. PubMed ID: 37866916
    [Abstract] [Full Text] [Related]

  • 33. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
    Ferreira S, Auray-Blais C, Boutin M, Lavoie P, Nunes JP, Martins E, Garman S, Oliveira JP.
    Clin Chim Acta; 2015 Jul 20; 447():96-104. PubMed ID: 26070511
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K, Yamamoto H.
    BMC Pharmacol Toxicol; 2017 Jun 07; 18(1):43. PubMed ID: 28592315
    [Abstract] [Full Text] [Related]

  • 35. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H.
    Mol Genet Metab; 2010 Jul 07; 100(3):257-61. PubMed ID: 20409739
    [Abstract] [Full Text] [Related]

  • 36. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
    Porto C, Pisani A, Rosa M, Acampora E, Avolio V, Tuzzi MR, Visciano B, Gagliardo C, Materazzi S, la Marca G, Andria G, Parenti G.
    J Inherit Metab Dis; 2012 May 07; 35(3):513-20. PubMed ID: 22187137
    [Abstract] [Full Text] [Related]

  • 37. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease.
    Hwang S, Lee BH, Kim WS, Kim DS, Cheon CK, Lee CH, Choi Y, Choi JH, Kim JH, Yoo HW.
    Medicine (Baltimore); 2022 Sep 16; 101(37):e30345. PubMed ID: 36123934
    [Abstract] [Full Text] [Related]

  • 38. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease.
    Ouyang Y, Chen B, Pan X, Wang Z, Ren H, Xu Y, Ni L, Yu X, Yang L, Chen N.
    Exp Ther Med; 2018 Apr 16; 15(4):3733-3742. PubMed ID: 29563981
    [Abstract] [Full Text] [Related]

  • 39. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
    Alharbi FJ, Baig S, Rambhatla SB, Vijapurapu R, Auray-Blais C, Boutin M, Steeds R, Wheeldon N, Dawson C, Geberhiwot T.
    Clin Chim Acta; 2020 Jan 16; 500():120-127. PubMed ID: 31654629
    [Abstract] [Full Text] [Related]

  • 40. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.
    Nose Y, Fujii H, Goto S, Kono K, Okamoto H, Watanabe K, Nishi S.
    Mol Genet Metab; 2023 Aug 16; 139(4):107634. PubMed ID: 37406430
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.